Nielk
Senior Member
- Messages
- 6,970
I want to point out that the CCC and ICC are criteria created by our experts - who really intimately know this disease by studying it and treating it for decades.
As far as what would happen to patients who have been diagnosed with CFS but don't fit hear criteria, they should be grandfathered in with the ME group so that they don't loose their disabilities. Of course, they should be treated for their symptoms and they should be tested to see whether they actually suffer from a different disease.
This is the same issue as what should happen with CFS patients who have been diagnosed with Fukuda but don't suffer from PEM.
I'm sure that everyone is keenly aware of the problem of faulty criteria (Oxford) used to select the cohorts for the PACE trial.
There are similar problems in the US. The CDC has and continues to refer to the Reeve's criteria which is very much the same as the Oxford.
Even though AHRQ has made a statement at the end of their report that they are removing studies using the Oxford criteria from their P2P report, doesn't mean that the other agencies have removed the Oxford or the Reeve's.
In my opinion, first and foremost, we need to identify what disease are we talking about?
Jason and Frisk have looked at the IOM criteria and compared them to the Fukuda, CCCand ICC. They both came to the same conclusion that the IOM criteria select a broader cohort. Jason says that due to the fact that there are no exclusions with the IOM, it selects 3x the size of Fukuda cohorts.
The IOM report was based on studies using faulty criteria. In addition, the panel was tasked to create easy criteria that can be used by any medical practitioner.
This over- simplification of a complex disease resulted in an overly broad definition.
As far as what would happen to patients who have been diagnosed with CFS but don't fit hear criteria, they should be grandfathered in with the ME group so that they don't loose their disabilities. Of course, they should be treated for their symptoms and they should be tested to see whether they actually suffer from a different disease.
This is the same issue as what should happen with CFS patients who have been diagnosed with Fukuda but don't suffer from PEM.
I'm sure that everyone is keenly aware of the problem of faulty criteria (Oxford) used to select the cohorts for the PACE trial.
There are similar problems in the US. The CDC has and continues to refer to the Reeve's criteria which is very much the same as the Oxford.
Even though AHRQ has made a statement at the end of their report that they are removing studies using the Oxford criteria from their P2P report, doesn't mean that the other agencies have removed the Oxford or the Reeve's.
In my opinion, first and foremost, we need to identify what disease are we talking about?
Jason and Frisk have looked at the IOM criteria and compared them to the Fukuda, CCCand ICC. They both came to the same conclusion that the IOM criteria select a broader cohort. Jason says that due to the fact that there are no exclusions with the IOM, it selects 3x the size of Fukuda cohorts.
The IOM report was based on studies using faulty criteria. In addition, the panel was tasked to create easy criteria that can be used by any medical practitioner.
This over- simplification of a complex disease resulted in an overly broad definition.
Last edited: